Loading clinical trials...
Loading clinical trials...
OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF FX-1006A IN SUBJECTS WITH TRANSTHYRETIN (TTR) AMYLOIDOSIS
Conditions
Interventions
Tafamidis
Locations
9
United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
FLENI
Buenos Aires, Argentina
Hospital Universitário Clementino Fraga Filho -HUCFF Universidade Federal do Rio de Janeiro
Rio de Jameiro, R.J., Brazil
Centre d'Investigation Clinique
Créteil, France
Universitatsklinikum Muenster
Münster, Germany
Centro per lo Studio e la Cura delle Amiloidosi Sistemiche IRCCS - Policlinico San Matteo
Pavia, Italy
Start Date
August 5, 2009
Primary Completion Date
July 8, 2020
Completion Date
July 8, 2020
Last Updated
July 29, 2021
NCT07223203
NCT00791492
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions